Clottu Aurélie, Horisberger Alice, Comte Denis
Service d'immunologie et allergie, CHUV, 1011 Lausanne.
Rev Med Suisse. 2021 Apr 7;17(733):684-689.
Systemic lupus erythematosus is a complex autoimmune disease that remains challenging to treat. Recent advances in the understanding of the pathogenesis of SLE pave the way for the evaluation of biologic medicine. The most promising therapeutic targets in SLE are those that interfere with B cells count or normal function, interferon inhibitors, JAK inhibitors and biologicals that alter the cytokines imbalance that characterizes SLE. Recent phase 3 clinical trials have evaluated the role of belimumab in lupus nephritis and the usefulness of anifrolumab in the treatment of moderate to severe SLE. Many more trials are currently underway and may improve the level of care of patients with SLE in the near future.
系统性红斑狼疮是一种复杂的自身免疫性疾病，治疗起来仍然具有挑战性。对系统性红斑狼疮发病机制认识的最新进展为生物药物的评估铺平了道路。系统性红斑狼疮中最有前景的治疗靶点是那些干扰B细胞数量或正常功能的靶点、干扰素抑制剂、JAK抑制剂以及改变系统性红斑狼疮特征性细胞因子失衡的生物制剂。最近的3期临床试验评估了贝利尤单抗在狼疮性肾炎中的作用以及阿尼鲁单抗在治疗中度至重度系统性红斑狼疮中的有效性。目前还有更多试验正在进行，可能在不久的将来提高系统性红斑狼疮患者的护理水平。
